BCAL Diagnostics Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2010

Location

Sydney NSW Australia

Primary Industry

Biotechnology

About

Based in Sydney, Australia, and founded in 2010 by co-founders Jayne Shaw, Dharmica Mistry, Ph.D., and Ron Philips, BCAL Diagnostics Pty Limited operates as a provider of non-invasive diagnostic technologies for improving early breast cancer detection for healthcare professionals and screening facilities. In June 2024, BCAL Diagnostics raised AUD 10.5 million in PIPE funding from Ellerston Capital and APS Foundation. As of 2024, the company is led by its CEOs, John Harrell and Shane Ryan. The company trades on ASX (Australian Securities Exchange) under the ticker symbol BDX. The company provides a wide range of diagnostic tools, such as blood-based tests for breast cancer detection, lipidomic analysis platforms, and liquid chromatography mass spectrometry (LCMS) systems. These tools are intended to improve existing imaging methods, like mammograms.

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Diagnostic Equipment

Website

www.bcaldiagnostics.com/

Verticals

HealthTech

Company Stage

Mature

Total Amount Raised

Subscriber access only

Deals

Deals Type
PIPE

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	BCAL Diagnostics	03 Jun 2024

Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.